Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

CagriSema in Type 2 Diabetes: Meta-Analysis

A 2026 Bayesian meta-analysis found clear benefits versus placebo, but the added HbA1c effect versus dose-matched semaglutide was uncertain.

Why we wrote this. The pooled results differ by comparator and outcome. This readout keeps the placebo findings separate from the more uncertain semaglutide comparison.

In this article (5 sections)
  1. The placebo comparisons showed large average changes
  2. The semaglutide comparison was outcome-specific
  3. Gastrointestinal events and discontinuation increased versus placebo
  4. How to read a Bayesian meta-analysis
  5. What this review does not establish

A 2026 systematic review and Bayesian meta-analysis found that CagriSema lowered HbA1c and body weight more than placebo in randomized trials of adults with type 2 diabetes. Against dose-matched semaglutide, the additional HbA1c reduction was modest and uncertain, while an additional weight reduction remained probable[1]. This was a synthesis of six trials, not a new randomized trial, and it does not support choosing or changing treatment without clinical review.

CagriSema combines cagrilintide, an amylin analogue, with semaglutide, a GLP-1 receptor agonist. The reviewers searched PubMed, Embase, CENTRAL and ClinicalTrials.gov through June 30, 2026. They included randomized controlled trials and used Bayesian random-effects models to produce posterior medians with 95% credible intervals.

The placebo comparisons showed large average changes

For CagriSema 2.4 mg versus placebo, the pooled between-group difference in HbA1c was minus 1.87 percentage points. The 95% credible interval ran from minus 2.08 to minus 1.62 percentage points[2]. The corresponding difference in percentage body-weight change was minus 12.69 percentage points, with a 95% credible interval from minus 13.78 to minus 11.61.

Those are average between-group estimates from selected trials. They are not promises for an individual. Baseline HbA1c, background medicines, adherence, trial duration and the estimand used to handle discontinuation can all affect the observed result. A percentage-point change in body weight is also different from a change measured in kilograms.

The review aligned efficacy or trial-product estimands where reporting allowed and examined treatment-policy estimates in sensitivity analyses. That distinction matters. A trial-product estimand asks a question closer to what happens while participants follow treatment as planned, whereas a treatment-policy estimand can include outcomes after discontinuation or rescue treatment. Estimates answering different questions should not be mixed without qualification.

The semaglutide comparison was outcome-specific

Against semaglutide 2.4 mg, CagriSema produced an estimated additional HbA1c reduction of minus 0.21 percentage points. Its 95% credible interval ranged from minus 0.62 to plus 0.11, crossing no difference[1]. The analysis therefore did not establish a clear incremental glycemic advantage over dose-matched semaglutide.

The estimated additional body-weight reduction versus semaglutide was minus 5.84 percentage points. The 95% credible interval ranged from minus 10.08 to minus 2.15, so the authors described the extra reduction as probable[2]. The interval is wide. It signals uncertainty about the size of the difference even though the direction favored CagriSema in the model.

Dose matching is central to the result. A comparison with semaglutide 2.4 mg does not automatically answer how CagriSema compares with every approved semaglutide product, dose or indication. Our semaglutide research overview separates trial populations and formulations rather than transferring one comparison across them.

Gastrointestinal events and discontinuation increased versus placebo

Compared with placebo, the relative risk of gastrointestinal adverse events was 2.27, with a 95% credible interval from 1.81 to 3.00. The relative risk of discontinuation because of adverse events was 3.16, with an interval from 1.50 to 6.87[1]. Relative risks do not show the absolute number of people affected unless the underlying event rates are also provided.

The estimates against semaglutide were less precise. That prevents a firm conclusion that the combination is more or less tolerable than dose-matched semaglutide. Safety comparisons can also be influenced by titration, follow-up, event definitions and how discontinuations are counted. A broad label such as gastrointestinal event can combine symptoms of different severity and duration.

The site's semaglutide safety section provides general context for that component. It should not be used to infer the safety profile of the fixed combination, because adding cagrilintide changes the intervention and the evidence base.

How to read a Bayesian meta-analysis

A 95% credible interval describes the range containing the parameter with 95% posterior probability under the model and its assumptions. It is not the same object as a frequentist confidence interval, though both express uncertainty. The result still depends on trial quality, between-study differences, selected priors and the amount of direct evidence available for each dose-comparator pair.

Only six trials contributed to the review. A random-effects model allows the underlying effect to vary, but a small evidence network can leave heterogeneity and rare harms poorly characterized. Meta-analysis can increase precision for reported outcomes; it cannot repair missing outcome data or create long-term evidence that the included trials did not collect.

What this review does not establish

The paper does not establish a personalized treatment sequence, an individual dose or a reason to combine separate products. It does not show that weight change necessarily produces fewer cardiovascular, kidney or mortality events. It also cannot define uncommon or delayed adverse effects when the underlying trials are too small or too short for those outcomes.

The most defensible reading is comparator-specific. CagriSema showed substantial average glycemic and weight effects against placebo. Against semaglutide 2.4 mg, added weight reduction appeared more convincing than added HbA1c reduction, while comparative tolerability remained uncertain. Future direct trials and longer follow-up are needed to refine those differences.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Was this a new CagriSema clinical trial?

No. It was a systematic review and Bayesian meta-analysis of six randomized trials representing 4,554 potentially eligible participants with type 2 diabetes.

How did CagriSema compare with placebo?

At the 2.4 mg dose analyzed, it produced larger average reductions in HbA1c and percentage body weight than placebo. These pooled averages do not predict an individual's response.

Was CagriSema clearly better than semaglutide 2.4 mg?

The added body-weight reduction remained probable, but the additional HbA1c reduction was modest and its credible interval crossed no difference.

What did the review find about tolerability?

Gastrointestinal events and adverse-event discontinuations increased versus placebo. Comparative estimates versus semaglutide were less precise, so relative tolerability remains uncertain.

Sources

  1. [1]Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis. 2026. PMID 42935221.Tier 1 · primary↩
  2. [2]NCBI PubMed EFetch record and abstract for PMID 42935221Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars